Deficits in spontaneous burrowing behavior in the rat bilateral monosodium iodoacetate model of osteoarthritis: An objective measure of pain-related behavior and analgesic efficacy

Osteoarthritis and Cartilage

Volumn 23, Issue 9, 2015, Pages 1605-1612

  Bryden, L A ^a   Nicholson, J R ^a   Doods, H ^a   Pekcec, A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Burrowing; Monosodium iodoacetate; Pain; Rat; Spontaneous behavior

Indexed keywords

CELECOXIB; IBUPROFEN; IODOACETIC ACID; MONOSODIUM IODOACETATE; MORPHINE; N (3 PYRIDAZINYL) 4 [3 (5 TRIFLUOROMETHYL 2 PYRIDINYLOXY)BENZYLIDENE] 1 PIPERIDINECARBOXAMIDE; NERVE GROWTH FACTOR ANTIBODY; UNCLASSIFIED DRUG; ANALGESIC AGENT;

ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURROWING; CONTROLLED STUDY; DRUG MECHANISM; LOCOMOTION; MALE; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; MOTOR ACTIVITY; WISTAR RAT;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; MALE; MORPHINE; MOTOR ACTIVITY; OSTEOARTHRITIS; PAIN; RATS, WISTAR;

EID: 84940451949     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2015.05.001     Document Type: Article

References (45)

1. Hinton R., Moody R.L., Davis A.W., Thomas S.F. Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 2002, 65:841-848.
2. Guzman R., Evans M.G., Bove S., Morenko B., Kilgore K. Mono-iodoacetate-induced changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol 2003, 31:619-624.
3. Liu P., Okun A., Ren J., Guo R.C., Ossipov M.H., Xie J., et al. Ongoing pain in the MIA model of osteoarthritis 2011, 493:72-75.
4. Le Graverand-Gastineau M.P. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets 2010, 11:528-535.
5. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
6. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.M., Guzman R.E., Juneau P.L., et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003, 11:821-830.
7. Fernihough J., Gentry C., Malcangio M., Fox A., Rediske J., Pellas T., et al. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 2004, 112:83-93.
8. Pomonis J.D., Boulet J.M., Gottshall S.L., Phillips S., Sellers R., Bunton T., et al. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 2005, 114:339-346.
9. Blackburn-Munro G. Pain-like behaviours in animals - how human are they?. Trends Pharmacol Sci 2004, 25:299-305.
10. Mogil J.S. Animal models of pain: progress and challenges. Nat Rev Neurosci 2009, 10:283-294.
11. Whiteside G.T., Adedoyin A., Leventhal L. Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans. Neuropharmacology 2008, 54:767-775.
12. Mogil J.S., Crager S.E. What should we be measuring in behavioral studies of chronic pain in animals?. Pain 2004, 112:12-15.
13. Vierck C.J., Hansson P.T., Yezierski R.P. Clinical and pre-clinical pain assessment: are we measuring the same thing?. Pain 2008, 135:7-10.
14. Hawker G.A., Stewart L., French M.R., Cibere J., Jordan J.M., March L., et al. Understanding the pain experience in hip and knee osteoarthritis-an OARSI/OMERACT initiative. Osteoarthritis Cartilage 2008, 16:415-422.
15. Dworkin R.H., Turk D.C., Farrar J.T., Haythornthwaite J.A., Jensen M.P., Katz N.P., et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113:9-19.
16. Andrews N., Legg E., Lisak D., Issop Y., Richardson D., Harper S., et al. Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain. Eur J Pain 2012, 16:485-495.
17. Deacon R.M. Burrowing in rodents: a sensitive method for detecting behavioral dysfunction. Nat Protoc 2006, 1:118-121.
18. Rutten K., Schiene K., Robens A., Leipelt A., Pasqualon T., Read S.J., et al. Burrowing as a non-reflex behavioural readout for analgesic action in a rat model of sub-chronic knee joint inflammation. Eur J Pain 2014, 18:204-212.
19. Rutten K., Robens A., Read S.J., Christoph T. Pharmacological validation of a refined burrowing paradigm for prediction of analgesic efficacy in a rat model of sub-chronic knee joint inflammation. Eur J Pain 2014, 18:213-222.
20. Jirkof P., Cesarovic N., Rettich A., Nicholls F., Seifert B., Arras M. Burrowing behavior as an indicator of post-laparotomy pain in mice. Front Behav Neurosci 2010, 4:165.
21. Jirkof P., Leucht K., Cesarovic N., Caj M., Nicholls F., Rogler G., et al. Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory mice. Lab Anim 2013, 47:274-283.
22. Jirkof P. Burrowing and nest building behavior as indicators of well-being in mice. J Neurosci Methods 2014, 234:139-146.
23. Huang W., Calvo M., Karu K., Olausen H.R., Bathgate G., Okuse K., et al. A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy. Pain 2013, 154:560-575.
24. Lau W., Dykstra C., Thevarkunnel S., Silenieks L.B., de Lannoy I.A., Lee D.K., et al. A back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain. Neuropharmacology 2013, 73:204-215.
25. Andrews N., Harper S., Issop Y., Rice A.S. Novel, nonreflex tests detect analgesic action in rodents at clinically relevant concentrations. Ann N Y Acad Sci 2011, 1245:11-13.
26. Cobos E.J., Ghasemlou N., Araldi D., Segal D., Duong K., Woolf C.J. Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia. Pain 2012, 153:876-884.
27. Guingamp C., Gegout-Pottie P., Philippe L., Terlain B., Netter P., Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum 1997, 40:1670-1679.
28. Matson D.J., Broom D.C., Carson S.R., Baldassari J., Kehne J., Cortright D.N. Inflammation-induced reduction of spontaneous activity by adjuvant: a novel model to study the effect of analgesics in rats. J Pharmacol Exp Ther 2007, 320:194-201.
29. Nagase H., Kumakura S., Shimada K. Establishment of a novel objective and quantitative method to assess pain-related behavior in monosodium iodoacetate-induced osteoarthritis in rat knee. J Pharmacol Toxicol Methods 2012, 65:29-36.
30. Hezareh M., Hessell A.J., Jensen R.C., van de Winkel J.G., Parren P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001, 75:12161-12168.
31. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013, 65:1795-1803.
32. Huggins J.P., Smart T.S., Langman S., Taylor L., Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012, 153:1837-1846.
33. Stevenson G.W., Mercer H., Cormier J., Dunbar C., Benoit L., Adams C., et al. Monosodium iodoacetate-induced osteoarthritis produces pain-depressed wheel running in rats: implications for preclinical behavioral assessment of chronic pain. Pharmacol Biochem Behav 2011, 98:35-42.
34. More A.S., Kumari R.R., Gupta G., Lingaraju M.C., Balaganur V., Pathak N.N., et al. Effect of iNOS inhibitor S-methylisothiourea in monosodium iodoacetate-induced osteoathritic pain: implication for osteoarthritis therapy. Pharmacol Biochem Behav 2013, 103:764-772.
35. Thakur M., Rahman W., Hobbs C., Dickenson A.H., Bennett D.L. Characterisation of a peripheral neuropathic component of the rat monoiodoacetate model of osteoarthritis. PLoS One 2012, 7:e33730.
36. Ferreira-Gomes J., Adães S., Sousa R.M., Mendonça M., Castro-Lopes J.M. Dose-dependent expression of neuronal injury markers during experimental osteoarthritis induced by monoiodoacetate in the rat. Mol Pain 2012, 8:50.
37. Ivanavicius S.P., Ball A.D., Heapy C.G., Westwood F.R., Murray F., Read S.J. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain 2007, 128:272-282.
38. Orita S., Ishikawa T., Miyagi M., Ochiai N., Inoue G., Eguchi Y., et al. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord 2011, 12:134.
39. Sherwin C.M., Huag E., Terkelsen N., Vadgma M. Studies on the motivation for burrowing by laboratory mice. Appl Anim Behav Sci 2004, 88:343-358.
40. Antoniou K., Malamas M., Drosos A. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opin Pharmacother 2007, 8:1719-1732.
41. Jones C.K., Peters S.C., Shannon H.E. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005, 312:726-732.
42. Combe R., Bramwell S., Field M.J. The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats?. Neurosci Lett 2004, 370:236-240.
43. Ahn K., Smith S.E., Liimatta M.B., Beidler D., Sadagopan N., Dudley D.T., et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011, 338:114-124.
44. Sokolove J., Lepus C.M. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis 2013, 5:77-94.
45. Sorge R.E., Martin L.J., Isbester K.A., Sotocinal S.G., Rosen S., Tuttle A.H., et al. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods 2014, 11:629-632.